Patents by Inventor Helene G. Bazin-Lee

Helene G. Bazin-Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144865
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
  • Publication number: 20220144833
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
  • Publication number: 20220119428
    Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)—active and toll-like receptor (TLR8)—active imidazoquinolines and oxoadenines.
    Type: Application
    Filed: December 30, 2021
    Publication date: April 21, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. BAZIN-LEE, Laura S. BESS, David A. JOHNSON
  • Patent number: 11274115
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: March 15, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventors: Helene G. Bazin-Lee, Jay T. Evans, David Burkhart, Michael Cochran, David A. Johnson
  • Patent number: 11248012
    Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: February 15, 2022
    Assignee: GLAXO SMIIHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, Laura S. Bess, David A. Johnson
  • Patent number: 11207404
    Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: December 28, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: David Burkhart, Michael Cochran, Christopher W Cluff, Daniel Larocque, Helene G. Bazin-Lee, Julien St-Jean
  • Publication number: 20210277038
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Application
    Filed: September 5, 2016
    Publication date: September 9, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
  • Patent number: 10919894
    Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 16, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, Yufeng Li
  • Publication number: 20210024553
    Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.
    Type: Application
    Filed: August 10, 2020
    Publication date: January 28, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. BAZIN-LEE, Laura S. BESS, David A. JOHNSON
  • Patent number: 10882876
    Abstract: The present invention provides novel phospholipidated imidazoquinolines as TLR7 and TLR8 agonists, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: January 5, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, David A. Johnson
  • Publication number: 20200345841
    Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.
    Type: Application
    Filed: April 15, 2020
    Publication date: November 5, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: David BURKHART, Michael COCHRAN, Christopher W. CLUFF, Daniel LAROCQUE, Helene G BAZIN-LEE, Julien ST JEAN
  • Patent number: 10774099
    Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)—active and toll-like receptor (TLR8)—active imidazoquinolines and oxoadenines.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: September 15, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, Laura S. Bess, David A. Johnson
  • Publication number: 20200223849
    Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n-moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 16, 2020
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Helene G. BAZIN-LEE, Yufeng LI
  • Patent number: 10646566
    Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 12, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: David Burkhart, Michael Cochran, Christopher W Cluff, Daniel Larocque, Helene G Bazin-Lee, Julien St Jean
  • Patent number: 10584125
    Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 10, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, Yufeng Li
  • Publication number: 20190375772
    Abstract: The present invention provides novel phospholipidated imidazoquinolines as TLR7 and TLR8 agonists, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: December 12, 2019
    Inventors: Helene G. BAZIN-LEE, David A. Johnson
  • Patent number: 10351582
    Abstract: The present invention provides novel phospholipidated imidazoquinolines of formula (I) as TLR7 and TLR8 agonists, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: July 16, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Helene G. Bazin-Lee, David A. Johnson
  • Publication number: 20180362560
    Abstract: The present invention provides novel phospholipidated imidazoquinolines of formula (I) as TLR7 and TLR8 agonists, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
    Type: Application
    Filed: December 12, 2016
    Publication date: December 20, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Helene G. BAZIN-LEE, David A. JOHNSON
  • Publication number: 20180291026
    Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 11, 2018
    Inventors: Helene G. BAZIN-LEE, Yufeng LI
  • Publication number: 20180273560
    Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.
    Type: Application
    Filed: December 12, 2016
    Publication date: September 27, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Helene G. BAZIN-LEE, Laura S. BESS, David A. JOHNSON